Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Eylea
Eylea
Bayer grapples with Eylea sales slowdown, sees trend continuing in 2023
Fierce Pharma
Tue, 02/28/23 - 10:41 pm
Bayer
earnings
Eylea
In showdown with Roche, Regeneron gears up for potential Eylea expansion amid Covid decline
Endpoints
Mon, 02/6/23 - 10:35 am
Regeneron
earnings
Eylea
In a win for Regeneron, Novartis' syringe for AMD drug declared 'unpatentable'
Endpoints
Thu, 01/26/23 - 05:05 pm
Regeneron
Novartis
Eylea
drug delivery
patents
Lucentis
Coherus pays out $32M for exclusive US commercialization rights to Eylea biosimilar
Endpoints
Tue, 01/10/23 - 06:40 pm
Coherus Biosciences
biosimilars
ophthalmology
Eylea
Regeneron
Roche's Vabysmo lands clinical counterpunch in ophthalmology brawl with Eylea
Fierce Pharma
Thu, 10/27/22 - 11:02 am
Roche
Genentech
Vabysmo
bispecific antibodies
Eylea
Regeneron, Bayer's Eylea nabs six months of pediatric exclusivity as competition waits to enter the market
Endpoints
Mon, 10/24/22 - 11:10 pm
Regeneron
Bayer
Eylea
pediatric exclusivity
biosimilars
Regeneron secures priority review for Eylea's use in infant retinopathy
Fierce Pharma
Wed, 10/12/22 - 11:40 pm
Eylea
Regeneron
retinopathy of prematurity
FDA
priority review
Bayer, Regeneron's eye drug shown to work at higher dose, longer intervals
Yahoo/Reuters
Thu, 09/8/22 - 04:33 pm
Bayer
Regeneron
Eylea
diabetic macular edema
wet age-related macular degeneration
Kodiak matches Regeneron’s Eylea in macular edema phase 3, lighting Beacon of hope after flop
Fierce Biotech
Tue, 08/9/22 - 06:34 am
Kodiak Sciences
Regeneron
Bayer
Eylea
macular edema
clinical trials
tarcocimab
Regeneron's Dupixent and Eylea Offset Drop in COVID-19 Antibody Sales
BioSpace
Wed, 08/3/22 - 09:19 pm
Regeneron
earnings
COVID-19
Eylea
Dupixent
Look out, Regeneron. As the threat from Roche's Vabysmo grows, one team of analysts slashes its Eylea sales estimate
Fierce Pharma
Mon, 07/25/22 - 10:00 pm
Regeneron
Eylea
Roche
Vabysmo
Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea®
BioSpace
Thu, 07/7/22 - 10:41 am
Alvotech
AVT06
biosimilars
clinical trials
Eylea
Regeneron's Eylea could lose 30% of its patients to Roche's Vabysmo over the next year: analyst survey
Fierce Pharma
Mon, 06/13/22 - 09:46 pm
Regeneron
Eylea
Vabysmo
Roche
wet-AMD
Why Regeneron Investors Shouldn't Fear Its Patent Cliff
Motley Fool
Thu, 05/26/22 - 10:08 am
Regeneron
patents
patent cliff
Eylea
With Bayer's new launches in infancy, Eylea and Xarelto still rule its pharma business—but for how long?
Fierce Pharma
Tue, 03/1/22 - 10:04 pm
Bayer
Eylea
Xarelto
drug launches
Kodiak's Eylea rival hits 'major disappointment' with failure in first of 6 phase 3 studies
Fierce Biotech
Wed, 02/23/22 - 09:28 pm
Kodiak Sciences
KSI-301
Eylea
Bayer
Regeneron
Roche pharma CEO Anderson talks up Vabysmo’s 'very strong launch' plans as Eylea battle looms
Fierce Pharma
Wed, 02/9/22 - 10:56 pm
Roche
Vabysmo
drug launches
Bill Anderson
Eylea
Roche grabs FDA okay for would-be blockbuster eye drug faricimab
Pharmaforum
Mon, 01/31/22 - 10:51 am
Roche
faricimab
Eylea
Bayer
Regeneron
FDA
Regeneron earns mid-stage win for higher dose of Eylea, hoping to refresh its sales pitch
Endpoints
Tue, 08/24/21 - 10:51 am
Regeneron
Eylea
clinical trials
wet age-related macular degeneration
Novartis says trials back Beovu safety in diabetic eye disease
Pharmaforum
Tue, 08/17/21 - 10:08 am
Novartis
Beovu
diabetic macular edema
Bayer
Regeneron
Eylea
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
next ›
last »